Table 1 Summary statistics of the MM1 and MM2 patient cohorts
Variable | MM2 Cohort | MM1 Cohort |
|---|---|---|
Patients | 703 | 720 |
Sex n (%) | ||
Female | 351 (49.9%) | 312 (43.3%) |
Male | 352 (50.1%) | 408 (56.7%) |
Race n (%) | ||
White | 575 (81.8%) | 614 (85.3%) |
Asian | 96 (13.7%) | 64 (8.9%) |
Native Hawaiian or other Pacific islander | 1 (0.1%) | 4 (0.6%) |
Black or African American | 23 (3.3%) | 13 (1.8%) |
American Indian or Alaska native | 3 (0.4%) | 1 (0.1%) |
Other | 5 (0.7%) | 7 (1.0%) |
Not reported | 0 (0.0%) | 17 (2.4%) |
Ig Type n (%) | ||
IgG | 403 (57.3%) | 389 (54.0%) |
IgA | 142 (20.2%) | 123 (17.1%) |
IgD | 10 (1.4%) | 7 (1.0%) |
IgE | 3 (0.4%) | 15 (2.1%) |
IgM | 3 (0.4%) | 1 (0.1%) |
Biclonal | 23 (3.3%) | 30 (4.2%) |
No Heavy Chain | 119 (16.9%) | 155 (21.5%) |
Median age [years] (min,max) | 73 (48,90) | 66 (30,91) |
Median time from diagnosis [months] (min,max) | 1.11 (0.3,52.9) | 42.8 (3,306) |
ISS Stage at study entry n (%) | ||
I | 324 (46.1%) | 458 (63.6%) |
II | 263 (37.4%) | 176 (24.0%) |
III | 115 (16.4%) | 86 (12.0%) |
Actual Treatment n (%) | ||
Rd | 349 (49.6%) | 359 (49.9%) |
IRd | 354 (50.4%) | 361 (50.1%) |
Planned Treatment n (%) | ||
Rd | 353 (50.2%) | 362 (50.3%) |
IRd | 350 (49.8%) | 358 (49.7%) |
